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 ABSTRACT: 
By virtue of being a localized treatment modality, radiotherapy is unable to deliver a 
tumoricidal radiation dose to tissues outside of the irradiated field. Ionizing radiation 
may result in the radiation damage mediated by a bystander like effect away from 
the irradiated field, but this response is likely to be modest when radiotherapy is the 
sole treatment modality. Over the last decade there has been a re-emergence of 
immune modulating therapies as an anti-cancer treatment. Clinical benefits from 
vaccines have on the whole been largely disappointing, but greater response rates 
have been observed from the immune checkpoint modulators. A clinical benefit of 
using such agents has been shown in disease sites such as melanoma and non-
small cell lung cancer. There is growing pre-clinical data and a number of case 
reports which suggest the presence of abscopal effects when radiotherapy is 
delivered during co-administration with immune checkpoint inhibitors, suggesting that 
this combination may lead to an enhanced tumor response outside of the primary 
treatment field. In this review, the mechanisms of such an enhanced out-of-field 
tumor response, the potential clinical utilities, the optimal radiotherapy delivery and 
considerations for clinical follow-up following treatment are discussed. 
 
 
 
  
MAIN MANUSCRIPT 
Introduction: 
In the last decade technological advances have permitted more accurate delivery of 
radiotherapy to target sites within the body, which reduces damage to surrounding 
normal tissue and allows radiotherapy dose escalation to maximize curability [1]. 
High dose, high precision and hence highly localized radiotherapy to tumor sites 
outside of the brain is known as stereotactic ablative body radiotherapy (SABR) [2]. 
SABR has been used to treat primary lung cancer with comparable control rates to 
surgery [3, 4]. SABR is also used in the treatment of oligometastatic disease, where 
a patient has only a small number of metastatic sites are detected by conventional 
imaging [5]. As the name suggests, SABR delivers high dose, hypofractionated 
treatment and hence an ablative dose. For example, in the treatment of early stage 
lung cancer, regimens of 54 to 60 Gy in 3 fractions are delivered in just over a week 
which is in stark contrast to a standard dose of 60 to 66 Gy delivered in 30 to 33 
fractions over 6 weeks [6]. When delivered with consideration for the tolerance of 
adjacent normal tissues SABR treatments are relatively free from significant toxicity 
or side-effects [6]. However, in the high dose region the ablative dose (e.g. for a 
patient receiving 54 Gy in 3 fractions with a maximum dose of up to 130% within the 
target volume, will in effect receive a biologically equivalent dose (BED) of up to 227 
Gy, assuming an α/β radio of 10) leads to intense radiation damage and hence a 
significant tissue response with an associated immune response [7]. This immune 
response can be observed clinically in lung SABR treatments as pneumonitis 
transforming into fibrosis in the surrounding normal lung [8]. Although this immune 
response to radiation is clearly undesirable, it may be possible to harness this effect 
and use it to target cancer cells not irradiated within the primary tumor. 
 In conjunction with the recent advances in radiotherapy delivery, over the last 
decade there has also been a greater understanding of the immune response to 
malignancy which has led to the development of a number of immune modulating 
agents [9, 10]. Agents such as the immune checkpoint modulators have been shown 
to lead to regression of a number of solid malignancies and in some cases, a 
prolonged complete response to treatment has been observed [11]. In addition to 
this, there is growing pre-clinical data and a growing number of case reports which 
suggest the presence of abscopal effects when radiotherapy is delivered during co-
administration with immune checkpoint inhibitors [12-15]. In the abscopal effect, an 
enhanced tumor response in disease locations which are outside of the primary 
treatment field and which have not received any radiation dose is observed [12, 16]. 
It is suggested that the ablative nature of radiotherapy treatment leads to an immune 
response which can be augmented by immune modulating agents [17]. The 
underlying cellular mechanisms driving these out-of-field responses is still poorly 
understood but a greater mechanistic understanding could provide significant 
therapeutic opportunities. One area of potential clinical use of the combination of 
SABR and immune modulating agents is in the setting of oligometastatic disease 
[18]. The term oligometastatic, initially suggested by Hellman and Wecchselman, 
describes the presence of a limited number of metastatic sites of disease, usually 
less than 6 in number [19]. If an oligometastatic state is in existence, the implication 
is that is there are no viable micrometatases and that all the metastases that are 
present have declared themselves [20]. Hence eradication of the oligometastases 
should lead to long term cure. In this setting the potential of enhanced in-field may 
lead to an increased chance of long term control and even if a patient’s disease is 
not truly oligometastatic and if there are clinically undetectable metastases 
elsewhere, immune mediated out of field responses may prevent progression of non-
irradiated undetectable metastasis and may led to an increased chance of a 
complete response. This review considers possible mechanisms of such an 
enhanced out of field tumor response, the potential clinical utilities, optimal 
radiotherapy delivery, the timing of immune modulation and any considerations for 
clinical follow-up after treatment. 
 
 
The immune response to malignancy 
It has been shown that the immune system can detect and respond to the presence 
of malignant cells [10, 21]. The immune response to cancer can be activated by the 
presence of antibodies to antigens on malignant cells, from tumor specific T-cells 
and tumor infiltrating lymphocytes [22-24]. It has been noted that in some cancers, 
the presence of tumor infiltrating immune cells correlates with clinical outcome [25]. 
Although the immune system may mount a response to cells which have undergone 
malignant transformation, in order to survive and proliferate tumors must develop the 
ability to evade surveillance and control by the host immune system [26]. Cancers 
use a variety of mechanisms to evade the immune system which include inhibition of 
tumor antigen presentation, secretion of immunosuppressive cytokines, recruitment 
of immunosuppressive cell types and inhibition of attack by immune cells [21, 27]. 
This ability to avoid immune destruction has been recently described as one of the 
new updated hallmarks of cancer [28].  
 
 
Immunotherapeutic approaches in the treatment of cancer 
Evasion of the immune system by cancer is essential to the process carcinogenesis, 
tumor development and metastasis, but modulation of the immune system may also 
be a potential therapeutic strategy. Immunotherapeutic strategies can be considered 
as either active or passive. Passive approaches involved the use of exogenous 
effectors of an immune response such as with humoral anti-tumor antibodies (e.g. 
Trastuzumab with targets and binds to the extra-cellular domain of the HER-2/neu 
receptor which interferes with receptor function and expression) or by a cellular 
adoptive approach such as with allogeneic transplantation [29]. Active approaches 
include non-specific immune modulation, therapeutic vaccines, modulation of T-cell 
function and oncolytic viruses.  Examples of these are shown in table 1 [30-48].  
 
Non-specific immune stimulation has been in routine clinical use for over a decade 
with the use of Interferon-α and interleukin-2 in the treatment of diseases such as 
melanoma and renal cell carcinoma. These agents act by modulating the immune 
system rather than by a direct cytotoxic effect [30]. However, as the name suggests, 
these agents are non-specific and produce significant side-effects, such as fatigue 
and fever, with only modest clinical benefit [31, 32, 49]. In contrast vaccine therapy is 
highly specific with the immune response targeted only to tumor antigens. Vaccine 
therapy can be directed against whole cells or directed to specific tumor antigens 
[50]. Despite early positive signals of response, larger studies of vaccine therapy 
both in the palliative or adjuvant setting have been on the whole disappointing and it 
is likely that vaccine therapy alone will not be efficacious strategy in anti-cancer 
treatment [51-53]. Oncolytic viruses have a dual mode of action. Viruses such as 
Talimogene laherparepvec are activated only in the malignant cell of interest [48]. 
When activated these viruses are directly cytotoxic to the malignant cell infected but 
they also trigger an immune response to the malignant cell, causing antigen 
presentation of components of the infected malignant cell and thus recognition of the 
malignant cell is changed and it becomes an immune target. 
 
Of emerging clinical interest are agents which modulate T-cell function. It has been 
shown that tumors can evade and then escape the immune system by producing 
immunosuppressive cytokines, such as interferon- ƴ (IFN-ƴ) either from the tumor 
cells directly or from cells within in the tumor microenvironment [54, 55]. These 
immunosuppressive cytokines lead to T-cell inactivation and hence a loss of immune 
response. A number of immune checkpoint inhibitors such as the anti–CTL antigen-4 
(CTLA-4) or anti–programmed death-1 (PD-1) antibodies which inhibit these 
cytokines by a number of mechanisms have been used in clinical trials and some of 
the agents are listed in table 1 [41, 44]. CTLA-4 is crucial in maintaining tolerance to 
self-antigens, hence preventing auto-immune disease and is a master regulator of T-
cell activation [56]. In malignancy and in the milieu of the tumor micro-environment 
CTLA-4 acts to reduce or inactivate the T-Cell response. In a normal immune 
response the T-cell receptor will bind to a presented antigen. In order for the T-cell to 
be activated CD28 must also bind to CD80 and CD86 on the surface of the antigen 
presenting cell to provide a co-stimulation of the T-cell.  CTLA-4 competitively 
competes with the CD28/CD80/CD86 complex and in the tumor micro-environment 
where CD80 and CD86 are depleted, the result is T-cell inhibition mediated by 
CTLA-4 [56]. CTLA-4 is also expressed on CD4+ regulatory T cells which are also 
known as (Tregs). On Tregs CTLA-4 induces the production of the highly 
suppressive cytokine transforming growth factor beta which also acts to down-
regulate T-cell function [57]. Thus CTLA-4 has a key role in reducing T-cell mediated 
immunity. Mono-clonal antibodies against CTLA-4 such as ipilimumab have been 
shown to be effective as single agents, with some durable clinical responses noted 
[41].  
 
PD-1 is an inhibitory receptor expressed on T-cells whose normal function is crucial 
for preventing the development of autoimmune disease [58]. PD-1 may not have an 
overarching role in the normal immune response but it is thought that the function of 
PD-1 is to limit normal tissue damage in the presence of inflammation [59]. Two main 
ligands of PD-1 (PD-L1 and PD-L2) have been identified and these bind to PD-1 to 
inhibit T-cell function and up-regulation of these, within tumours, is common and is 
associated with a poor prognosis [60]. A number of PD-L1 and PD-L2 inhibitors have 
been shown to be effective across a range of tumor sites [44, 45]. This mechanism is 
illustrated in figure 1 and a summary of the currently available PD-1 inhibitors is 
shown in table 2 [28, 45-47, 61-63]. 
 
Why the combination of immunotherapy with radiotherapy may be synergistic. 
Out of field effects following radiotherapy treatment, mediated by a number of 
different mechanisms, have been previously described [64]. One of the clinical 
manifestations of this, the abscopal effect, has been described in a number of case 
reports [65-68]. As stated earlier, abscopal effects have been reported when 
radiotherapy has been delivered to patients on immune modulating agents [12, 15, 
69]. In a seminal experiment by Demaria et al, radiation responses were compared 
between immunocompetent and T-cell deficient (nude) mice each with two tumors. 
Both sets of mice received irradiation to one tumor only, both sets demonstrated a 
retardation of growth in the irradiated tumor but only the immunocompetent mice had 
growth retardation in the non-irradiated tumor [70]. The authors went onto 
hypothesize that the abscopal effect must be in some part immune mediated and is 
T-cell dependent [71].  
 
So might the combination of ionizing radiation and immune modulation be 
synergistic? The accepted key mechanism of cell death following radiotherapy is that 
radiation induced damage mediated by free radicals to cellular structures, in 
particular the DNA and the production of DNA double-strand breaks, which in turn 
leads to apoptosis when the damage is not repaired [72, 73]. However there is 
longstanding evidence that radiation exposure can lead to non-targeted effects, 
specifically bystander signalling mediated by cytokine release [64]. These have been 
classified into three distinct categories [74]. Firstly, classical bystander effects where 
irradiated cells signal with non-irradiated cells within a tissue, for example under 
conditions of localised irradiation including very low dose exposures. Secondly, 
abscopal effects, as described above, where responses at sites outside the 
treatment field are observed. A third category have been termed cohort effects 
where variable dose regions are observed typically within tumours receiving 
advanced radiotherapies where intercellular signalling leading to out-of-field effects 
can also play a role [75, 76]. However, in all three of these categories, it is also 
thought that radiotherapy, through direct cellular damage, leads to antigen 
presentation and may trigger an immune response [17]. Key to this process is the 
involvement of the tumor micro-environment [77, 78]. Ionizing radiation induces key 
chemokines, such as IFN-ƴ, CXCL9, CXCL10, and CXCL16, which attract effector T 
cells to the tumor by increasing T-cell motility and vascular permeability to T-cells 
[79-81]. Furthermore, following radiation, tumor cells may up-regulate many key cell 
surface ligands that increase the probability of antigen presentation to cytotoxic T-
cells in a process known as immunogenic modulation [82]. Other elements of 
immunogenic modulation include changes in the mechanism of antigen presentation 
and translocation of calreticulin to the cell surface [82-85]. It has also been 
suggested that modulated radiation induced immune responses may show a long 
duration of effect [86]. Thus the combination of radiotherapy and immune modulation 
represents a possible new paradigm shift in the management of advanced 
malignancy [87]. 
 
Following the US Food and Drug Administration approval of Sipuleucel-T for the 
treatment of advanced hormone resistant prostate cancer there is has been a re-
emergence of interest in vaccine therapy [35]. A number of pre-clinical and clinical 
studies have examined the effects of combining radiotherapy with vaccines, the 
rationale behind this combination is that the immune response mediated by 
radiotherapy may enhance the efficacy of the vaccine or vice versa. A range of 
vaccine types have been used in combination with radiotherapy and examples of the 
human studies are listed in table 3 [88-93]. At present vaccine therapy with 
radiotherapy is confined to early phase studies across a range of tumor types such 
as lung cancer [94]. Furthermore, the optimal radiotherapy dose and scheduling of 
vaccine delivery around radiotherapy will likely depend on the vaccine and tumor 
type and this will require further clinical investigation [95]. 
 
A number of case reports of abscopal effects with the combination of CTLA-4 
inhibitors and radiotherapy have led to interest in this combination [12, 69]. However 
there are also case reports of immune mediated abscopal responses in patients who 
have not responded to CTLA-4 inhibitors, hence the mechanism of this interaction is 
not clear [15]. Agents such as Ipilumimab in these settings used as monotherapy 
may not be entirely effective in triggering an immune response against the cancer. 
But, when radiotherapy is delivered, the subsequent immune response in addition to 
the CTLA-4 inhibitor is sufficient to trigger a T-cell mediated response to the 
malignant cells. Of note, both intra and inter-personal factors, both in terms of tumor 
heterogeneity and immune programming most probably will be determinants of 
differential responses. Of particular interest is the combination of anti-PD-1 
antibodies with radiotherapy. The unique role of PD-1 in down-regulating the immune 
response to inflammation suggests that turning off this pathway in combination with 
radiotherapy delivery may lead to an enhanced response beyond that seen with anti-
PD-1 therapy alone [59]. In a mouse glioma model, the combination of a constructed 
anti-PD-1 antibody and stereotactic radiotherapy leads to long term survival 
supporting the efficacy of this combination [13]. In another murine model of breast 
and colorectal carcinoma, enhanced tumor control was seen with the combination of 
radiotherapy and an anti-PD-1 antibody [14].  
 
Is radiation dose and fractionation important? 
Considering the variables in radiotherapy delivery along with immune modulating 
agents, it may be hypothesized that higher doses of radiotherapy may lead to 
increased DNA damage and hence an enhanced immune response. In preclinical 
studies, low dose irradiation has been shown to increase T-cell migration into the 
irradiated field [96]. It has also been suggested that radiotherapy doses from as low 
as 2 Gy but up to 20 Gy may be sufficient to trigger immunogenic cell death [17]. In 
the case reports of an abscopal effect with the combination of radiotherapy and 
ipilumimab, hypofractionated doses of 30 Gy delivered in 5 fractions and 28.5 Gy 
delivered in 3 fractions were used but these do not represent as high a BED as to 
those seen in SABR (BED of 48 Gy, assuming an α/β ratio of 10 for the tumor as 
compared of a BED of 151 Gy with a SABR type dose of 54 Gy delivered in 3 
fractions) [12, 15]. Given the high local and distant control rates in these reports, 
might immunotherapy provide some compensation for the lower radiation doses 
delivered? However, in the era of high local control with typical SABR doses, 
maintaining good local control is still a key goal and future clinical studies of 
radiotherapy combinations with immunotherapy in oligometastatic disease are likely 
to use SABR type doses to avoid compromise on local control. It has been shown 
that fractionated but not single dose radiotherapy induces an immune mediated 
abscopal effect; hence if SABR doses are to be used, they should be fractionated to 
some extent [97]. What is almost certain is that the immune effect of radiotherapy is 
very likely to depend on the tumor type and immune modulation used. Although 
differences in radiotherapy dose, fractionation regimens used and the nature of 
radiation delivery (photons as comparable to particle beams) will be factors in 
engendering an abscopal response, where possible and for the purposes of 
designing high quality controlled studies, radiotherapy delivery should be 
standardized where possible [98]. 
 
Issues for clinical follow-up in the setting of immune modulation 
Single agent immune modulating studies have poor clinical response rates. For 
example in a study of ipilumimab in melanoma the best overall response (complete 
or partial response) rate was 10.9% [41]. However, a minority of patients achieve 
long-term disease control often requiring several months to demonstrate an objective 
response. This slow to emerge, but prolonged and durable effect of immunotherapy 
is a feature of many of the clinical studies [11]. Hence in any studies examined the 
combination of immune modulating agents must undertake careful and prolonged 
follow-up. Furthermore, early termination of such studies on the grounds of futility 
must not be at the expense of missing an important late effect.  
 
 
 
Conclusions 
Radiotherapy has powerful effect on the tumor micro-environment with the potential 
to reverse the immunosuppressive state present in malignancy. Combinations of 
immune modulating agents and radiotherapy look promising both in over-coming 
local resistance to radiotherapy and in generating an out of field or abscopal effect. 
Future studies of the many possible combinations of immune modulating agents and 
radiotherapy are urgently needed to explore the potentially powerful abscopal effects 
reported in animal models and case reports to date. If the early promise from these 
studies is translated into a larger scale clinical benefit, then the combination of 
radiotherapy and immunotherapy may truly represent a paradigm shift in 
oligometastatic disease. 
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FIGURE CAPTIONS 
 
Figure 1:  
This schema illustrates the 3 various scenarios in a T-cell response to a malignant 
cell: 
A. This represents the normal activated T-cell response to antigen presenting cell or 
in the case of malignancy, a tumor cell. Following antigen presentation, the binding 
of CD-28 with CD-80 /CD-86 leads to T-cell activation and which in turn leads to 
increased T-Cell proliferation and cytokine production. 
B. This represent immune escape by the tumor in which the tumor derived PD-L1 
binds to PD-D on the T-cell leading to a suppressed T-cell Response with decreased 
T-cell Proliferation and cytokine production. 
C. Illustrates the impact of PD-1 ligand inhibition and thus restored T-cell function. 
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Table 1: Examples of Active Immunotherapeutic Approaches 
 
Non-specific 
immune stimulation 
 Cytokines (e.g. Interleukin-2, Interferon-α) [30-32] 
 Killer-cell immunoglobulin-like receptors antagonists [33] 
 Indoleamine 2,3-dioxygenase (IDO) pathway inhibitors [34] 
Therapeutic 
vaccines 
 Sipuleucel-T (prostate carcinoma) [35] 
 Anti-MAGE-A3 vaccine (non-small cell lung cancer and 
others) [36] 
 Racotumomab – anti N-glycolil (lung carcinoma, breast 
carcinoma, melanoma) [37] 
 Tergenpumatucel-L – (lung carcinoma) [38] 
Modulate T-Cell 
function 
 CD137 agonism [39] 
 CD40 agonism [40] 
 CTLA-4 inhibition [41] 
 LAG-3 inhibition [42] 
 OX-40 agonism [43] 
 PD-1 inhibition [44] 
 PD-L1 inhibition [45] 
 PD-L2 inhibition [46, 47] 
Oncolytic viruses  Talimogene laherparepvec (T-VEC, melanoma) [48] 
 
 
  
Table(s)
Table 2:  Summary of PD-1 and PD-L1 checkpoint inhibitors in clinical development 
 
Agent Classification Mode of action 
AMP-225 [61] Recombinant Fusion Protein 
Blocks interaction between PD-1 and B7-
H1 
BMS-936559 
[45] 
Humanised anti-PD-L1 monoclonal 
antibody Blocks PD-L1 binding to PD-1 and CD80 
MEDI4736 
[61] 
Humanised anti-PD-L1 monoclonal 
antibody Blocks PD-L1 binding to PD-1 and CD80 
MPDL3280A 
[63] 
Humanised anti-PD-L1 monoclonal 
antibody Blocks PD-L1 binding to PD-1 and CD80 
Nivolumab [47] 
Humanised anti-PD-1 monoclonal 
antibody Blocks PD-1 binding to PD-L1 and PD-L2 
Pembrolizumab 
[46]  
Humanised anti PD-1 monoclonal 
antibody Blocks PD-1 binding to PD-L1 and PD-L2 
Pidilizumab [62] 
Humanised anti-PD-1 monoclonal 
antibody Blocks PD-1 binding to PD-L1 and PD-L2 
  
  
Table 3:  Vaccines which have been delivered in conjunction with radiotherapy in human 
subjects 
Vaccine Class Agent Primary Tumor Type  
Dendritic Autologous immature dendritic 
cells 
Hepatoma [88] 
Autologous dendritic cells Numerous [89] 
Viral  Pox-based vaccine Prostate [90] 
Smallpox and fowlpox vaccine 
targeting carcinoembryonic 
antigen (CEA) 
Colorectal [91] 
Protein Multiple peptide based vaccine Esophageal [92] 
Whole Cell Pancreatic Tumor Cell Vaccine 
(GVAX) 
Pancreas [93] 
Nucleic Acid None at present N/A 
 
 
